• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Novartis Acquires Endocyte for $2.1 Billion

    Gabrielle Lakusta
    Oct. 18, 2018 03:25PM PST
    Biotech Investing
    NASDAQ:ECYT

    Novartis will benefit from the acquisition by expanding its radioligand therapy platform, while Endocyte and its shareholders will receive a premium price for the deal.

    In an all cash deal, Novartis (NYSE:NVS,SWX:NOVN) has acquired Endocyte (NASDAQ:ECYT) for US$2.1 billion.

    Novartis benefits from the acquisition by expanding its radioligand therapy (RLT) platform, while Endocyte and its shareholders will receive a premium price for the deal. Novartis will acquire each share at US$24 — which represents a 54 percent premium in value to its share price at US$15.56 as of market close October 17.

    “The global reach and expertise of Novartis in developing and commercializing RLT therapies will be critical in efforts for patients to benefit from these therapies as quickly as possible,” Mike Sherman, CEO of Endocyte, said in the press release.

    Endocyte is working with Centerview Partners, Faegre Baker Daniels and Jefferies as lead financial advisor, legal counsel and financial advisor respectively.

    According to the release, the transaction is expected to close in the first half of 2019 following approval from Endocyte stockholders, antitrust and regulatory approvals among additional customary closing conditions. The company will continue operating as an independent company until it closes.

    Novartis plans to “accelerate development” of Endocyte’s innovative RLT therapies, which have “significant sales potential,” according to the press release.

    Endocyte acquired the exclusive worldwide licensing rights to PSMA-617 agents from the private, German-based ABX.

    Lu-PSMA-617 is an RLT targeting a specific group of prostate cancer patients. 80 percent of patients in this unique group have metastatic castration-resistant prostate cancer (mCRPC), which may benefit from the treatment. Endocyte is currently enrolling patients for the Phase 3 Vision trial.

    Aside from this set of drugs, the company also has two CAR-T programs: one for a bone cancer, while the other is in pre-clinical development.

    Novartis is a global company focused on a variety of healthcare needs such as neuroscience, respiratory, oncology, ophthalmology and more.

    Investor takeaway

    Over the trading period Thursday, investors have shown enthusiasm in the acquisition. Endocyte’s share price increased over 50 percent to US$23.40.

    TipRanks shows one analyst, David Nierengarten with Wedbush Securities, downgraded the company from outperform to neutral from the acquisition.

    Investors can follow both companies’ news over the next to monitor the acquisition until its close in the first half of 2019. Investors can follow additional information on Endocyte’s website regarding its pipeline and the Vision trial.

    Don’t forget to follow @INN_LifeScience for real-time updates!

    Securities Disclosure: I, Gabrielle Lakusta, hold no direct investment interest in any company mentioned in this article.

    nasdaq:ecyt
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Latest News

    Seegnal Inc. Announces Extension of Maccabi Health Services Contract

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    Ă—